News

News 02.02.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...

News 01.02.2026 CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration...

News 29.01.2026 Schlieren, Zurich – DiNAMIQS has appointed Kathrin Schneider as its new Head of Business Development for Europe and the Asia-Pacific region (APAC). According to the Schlieren-based life sciences company, she has experience in establishing structures that enable sustainable, long-term growth. DiNAMIQS, based in the Bio-Technopark Schlieren-Zurich, has expanded its management team...

News 19.01.2026 We are pleased to announce that our acquisition of Doppl SA, including the Sun Bioscience technology, has officially been completed. This milestone expands our capabilities in human-relevant 3D biology and strengthens the support we offer across preclinical research. Doppl brings a distinctive organoid technology portfolio featuring tessellated organoid arrays, a leading biobank,...

News 15.01.2026 Unlike typical award programs, this recognition is based entirely on platform performance metrics, reflecting real activity and real outcomes across global R&D teams. Over the past year, scientists requested and completed studies spanning: 🔹 in vitro toxicology 🔹 pharmacology and assay development 🔹 cell culture and characterization All delivered through an on-demand procurement workflow. Performance indicators...